FiercePharma

Vertex, CRISPR's gene-editing therapy Casgevy wins early FDA nod to treat beta thalassemia

Vertex Pharmaceuticals and CRISPR Therapeutics have scored an FDA approval for their gene-editing therapy Casgevy (exa-cel) to treat transfusion-dependent beta thalassemia (TDT). The approval comes ...
Yahoo Finance

What Vertex Pharmaceuticals (VRTX)'s FDA Breakthrough for Povetacicept Means for Kidney Disease Pipeline

Vertex Pharmaceuticals recently announced that the FDA has granted Breakthrough Therapy Designation to povetacicept for IgA nephropathy, along with key clinical advancements in its kidney disease ...

Vertex Pharmaceuticals Incorporated: Vertex Presents New Data Across Portfolio of Cystic Fibrosis Medicines Including ALYFTREK at the North American Cystic Fibrosis Conference

Data presented on outcomes following treatment with CFTR modulators add to growing body of evidence that reduced level of sweat chloride is associated with improved clinical outcomes, particularly ...
FierceBiotech

Vertex posts full pain data ahead of FDA ruling, unpacking combo results, Vicodin miss and stellar safety

Vertex has reported phase 3 data on its near-approval pain drug candidate suzetrigine, shedding light on how the non-opioid painkiller combines with ibuprofen and why the prospect failed to match a ...
FierceBiotech

No pain, only gain for Vertex: FDA greenlights late-stage trial for nonopioid pain drug

After talks with the FDA, Vertex Pharmaceuticals has been given the go-ahead to advance its non-opioid pain killer into phase 3 trials, which are set to begin in the last quarter of this year. The ...
Business Wire

Vertex Announces FDA Clearance of Investigational New Drug Application for VX-407 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug Application (IND) ...
FiercePharma

Vertex snags FDA nod for once-daily cystic fibrosis triplet Alyftrek as switch from Trikafta kicks off

As Vertex Pharmaceuticals reels from a painful trial readout for its pain candidate suzetrigine, the Boston biotech has chalked up a win in its specialty area of cystic fibrosis. The FDA has approved ...
Business Wire

Vertex Announces FDA Acceptance of New Drug Application for Vanzacaftor/Tezacaftor/Deutivacaftor, a Next-In-Class Triple Combination Treatment for Cystic Fibrosis

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug ...
The Motley Fool

Is Vertex Pharmaceuticals a Buy Now That the FDA Approved Its New Pain Drug?

The U.S. Food and Drug Administration approved a new prescription-strength pain reliever from Vertex Pharmaceuticals on Jan. 30, 2025. Journavx is a non-opioid drug that prevents peripheral nerves ...